Literature DB >> 29054135

Alterations in the Timing of Huperzine A Cerebral Pharmacodynamics in the Acute Traumatic Brain Injury Setting.

Ugur Damar1, Roman Gersner1, Joshua T Johnstone2, Kush Kapur1, Stephen Collins2, Steven Schachter3, Alexander Rotenberg1.   

Abstract

Traumatic brain injury (TBI) may affect the pharmacodynamics of centrally acting drugs. Paired-pulse transcranial magnetic stimulation (ppTMS) is a safe and noninvasive measure of cortical gamma-aminobutyric acid (GABA)-mediated cortical inhibition. Huperzine A (HupA) is a naturally occurring acetylcholinesterase inhibitor with newly discovered potent GABA-mediated antiepileptic capacity, which is reliably detected by ppTMS. To test whether TBI alters cerebral HupA pharmacodynamics, we exposed rats to fluid percussion injury (FPI) and tested whether ppTMS metrics of cortical inhibition differ in magnitude and temporal pattern in injured rats. Anesthetized adult rats were exposed to FPI or sham injury. Ninety minutes post-TBI, rats were injected with HupA or saline (0.6 mg/kg, intraperitoneally). TBI resulted in reduced cortical inhibition 90 min after the injury (N = 18) compared to sham (N = 13) controls (p = 0.03). HupA enhanced cortical inhibition after both sham injury (N = 6; p = 0.002) and TBI (N = 6; p = 0.02). The median time to maximum HupA inhibition in sham and TBI groups were 46.4 and 76.5 min, respectively (p = 0.03). This was consistent with a quadratic trend comparison that projects HupA-mediated cortical inhibition to last longer in injured rats (p = 0.007). We show that 1) cortical GABA-mediated inhibition, as measured by ppTMS, decreases acutely post-TBI, 2) HupA restores lost post-TBI GABA-mediated inhibition, and 3) HupA-mediated enhancement of cortical inhibition is delayed post-TBI. The plausible reasons of the latter include 1) low HupA volume of distribution rendering HupA confined in the intravascular compartment, therefore vulnerable to reduced post-TBI cerebral perfusion, and 2) GABAR dysfunction and increased AChE activity post-TBI.

Entities:  

Keywords:  cerebral pharmacodynamics; epilepsy; huperzine A; transcranial magnetic stimulation; traumatic brain injury

Mesh:

Substances:

Year:  2017        PMID: 29054135      PMCID: PMC5784790          DOI: 10.1089/neu.2017.5258

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  29 in total

Review 1.  Transcranial magnetic stimulation in neurology.

Authors:  Masahito Kobayashi; Alvaro Pascual-Leone
Journal:  Lancet Neurol       Date:  2003-03       Impact factor: 44.182

2.  Traumatic brain injury elicits similar alterations in α7 nicotinic receptor density in two different experimental models.

Authors:  Peter-Georg Hoffmeister; Cornelius K Donat; Martin U Schuhmann; Cornelia Voigt; Bernd Walter; Karen Nieber; Jürgen Meixensberger; Reinhard Bauer; Peter Brust
Journal:  Neuromolecular Med       Date:  2010-09-21       Impact factor: 3.843

Review 3.  Transcranial magnetic stimulation: a primer.

Authors:  Mark Hallett
Journal:  Neuron       Date:  2007-07-19       Impact factor: 17.173

4.  Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease.

Authors:  Zi-Qiang Shao
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy.

Authors:  M Amélia Santos; Karam Chand; Sílvia Chaves
Journal:  Future Med Chem       Date:  2016-10-24       Impact factor: 3.808

6.  Long-term outcome of patients with disorders of consciousness with and without epileptiform activity and seizures: a prospective single centre cohort study.

Authors:  Angelo Pascarella; Luigi Trojano; Vincenzo Loreto; Leonilda Bilo; Pasquale Moretta; Anna Estraneo
Journal:  J Neurol       Date:  2016-07-14       Impact factor: 4.849

7.  Measures of cortical inhibition by paired-pulse transcranial magnetic stimulation in anesthetized rats.

Authors:  Andrew M Vahabzadeh-Hagh; Paul A Muller; Alvaro Pascual-Leone; Frances E Jensen; Alexander Rotenberg
Journal:  J Neurophysiol       Date:  2010-12-15       Impact factor: 2.714

8.  A phase II trial of huperzine A in mild to moderate Alzheimer disease.

Authors:  M S Rafii; S Walsh; J T Little; K Behan; B Reynolds; C Ward; S Jin; R Thomas; P S Aisen
Journal:  Neurology       Date:  2011-04-19       Impact factor: 9.910

Review 9.  Translational neuromodulation: approximating human transcranial magnetic stimulation protocols in rats.

Authors:  Andrew M Vahabzadeh-Hagh; Paul A Muller; Roman Gersner; Abraham Zangen; Alexander Rotenberg
Journal:  Neuromodulation       Date:  2012-07-10

10.  Expression of GABA receptor subunits in the hippocampus and thalamus after experimental traumatic brain injury.

Authors:  Meinrad Drexel; Noora Puhakka; Elke Kirchmair; Heide Hörtnagl; Asla Pitkänen; Günther Sperk
Journal:  Neuropharmacology       Date:  2014-09-16       Impact factor: 5.250

View more
  2 in total

1.  Craniectomy Effects on Resting State Functional Connectivity and Cognitive Performance in Immature Rats.

Authors:  Saman Sargolzaei; Yan Cai; Melissa J Walker; David A Hovda; Neil G Harris; Christopher C Giza
Journal:  Annu Int Conf IEEE Eng Med Biol Soc       Date:  2018-07

2.  Biomarkers Obtained by Transcranial Magnetic Stimulation of the Motor Cortex in Epilepsy.

Authors:  Melissa Tsuboyama; Harper Lee Kaye; Alexander Rotenberg
Journal:  Front Integr Neurosci       Date:  2019-10-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.